Long-term prognosis after achieving SVR in cirrhotic patients with HCV: significance of portal vein and portosystemic shunts

Long-term prognosis after achieving SVR in cirrhotic patients with HCV: significance of portal vein and portosystemic shunts - Portosystemic Shunts and DAA Therapies

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037785

Enrollment

Registered

2019-08-24

Start date

2019-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cirrhotic patients with HCV after achieving SVR by DAA therapies

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients diagnosed has having compensated cirrhosis at baseline of DAA therapies in whom SVR had been obtained at least 3 years prior to the start of this study

Exclusion criteria

Exclusion criteria: lost-to-follow up

Design outcomes

Primary

Measure	Time frame
Cumulative occurrence of portal hypertension events up to 3 years after achieving SVR	—

Countries

Japan

Contacts

Public ContactYoshihito Uchida

Saitama Medical University Department of Gastroenterology & Hepatology

y_uchida@saitama-med.ac.jp+81(0)49-276-1198

Outcome results